

Pradeep Harish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1859447/publications.pdf>

Version: 2024-02-01

10
papers

113
citations

1478505

6
h-index

1588992

8
g-index

11
all docs

11
docs citations

11
times ranked

182
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1016-1026.	7.3	30
2	Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy. <i>Human Molecular Genetics</i> , 2019, 28, 1694-1708.	2.9	28
3	Progress on Gene Therapy, Cell Therapy, and Pharmacological Strategies Toward the Treatment of Oculopharyngeal Muscular Dystrophy. <i>Human Gene Therapy</i> , 2015, 26, 286-292.	2.7	18
4	Knockdown of Muscle-Specific Ribosomal Protein L3-Like Enhances Muscle Function in Healthy and Dystrophic Mice. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 457-464.	3.6	11
5	Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6059.	4.1	9
6	Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease. <i>Frontiers in Physiology</i> , 2020, 11, 184.	2.8	9
7	Advances in emerging therapeutics for oculopharyngeal muscular dystrophy. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 693-701.	0.8	3
8	A pilot study to elucidate effects of artificial selection by size on the zebrafish (<i>Danio rerio</i>) fast skeletal muscle transcriptome. <i>Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology</i> , 2019, 233, 65-73.	1.8	3
9	Gene Therapy for Oculopharyngeal Muscular Dystrophy. , 2019, , 549-564.		2
10	Nuclear PABPN1 aggregates in OPMD: correlation study and therapy. <i>Neuromuscular Disorders</i> , 2017, 27, S202-S203.	0.6	0